| Income Statement | 2025-08-31 | |||
|---|---|---|---|---|
| Revenue | 705.923 | |||
| Cost of goods sold | 2.72 | |||
| Gross profit | 703.203 | |||
| Research and development | 8,238.757 | |||
| General and administrative | 4,345.183 | |||
| Total operating expenses | 12,583.94 | |||
| Loss from operations | -11,880.737 | |||
| Interest income | 3.017 | |||
| Unrealized loss on marketable securities | -33.714 | |||
| Total other income (loss) | -30.697 | |||
| Net loss | -11,911.434 | |||
| Less net loss attributable to non-controlling interest | -9.593 | |||
| Net loss attributable to lexaria shareholders | -11,901.841 | |||
| Foreign currency translation adjustment | -50.519 | |||
| Total comprehensive loss | -11,952.36 | |||
| - basic and diluted | 17,998,715 | |||
| Basic and diluted loss per share | -0.66 | |||
Lexaria Bioscience Corp. (LEXXW)
Lexaria Bioscience Corp. (LEXXW)